35 results about "Coated drugs" patented technology

A pharmaceutical composition containing a metal oxide coated particle comprising 1) an amorphous solid dispersion (ASD) core containing an active pharmaceutical ingredient (API) and a polymer; and 2) a metal oxide coating, and the method of making said metal oxide coated particle by atomic layer deposition (ALD). The metal oxide coated particle is useful because it prevents the ASD from crystallization and helps maintain the ASD in an amorphous form.

The invention discloses a high-utilization-rate ginseng active ingredient medicinal preparation and a preparation method thereof, and relates to the technical field of medicines. The high-utilization-rate ginseng active ingredient pharmaceutical preparation is prepared from chitosan coated drug-loaded porous silicon dioxide composite nanoparticles and a drug-loaded MIL-101 metal organic framework matrix material, chitosan-coated drug-loading porous silicon dioxide composite nanoparticles are loaded on the surface of a drug-loading MIL-101 metal organic framework base material, and sodium alginate and a chitosan gel material are subjected to cross-linking connection, so that independent coating is formed, the framework base material and the composite nanoparticles are connected into a whole, the encapsulation performance and the drug loading capacity are improved, and the drug-loading capacity of the drug-loading MIL-101 metal organic framework composite nanoparticles is improved. Furthermore, the loading and the loading stability of the ginsenoside are improved, the adverse effects of gastric juice and gastrointestinal peristalsis on the activity of the ginsenoside are effectively reduced, the release and the absorption of the ginsenoside in intestinal tracts are remarkably enhanced, and the bioavailability is relatively high.

The invention belongs to the technical field of medicines, and particularly relates to a linarin targeted slow-release nano drug-loading system as well as a preparation method and application thereof. A polylactic acid-polyglycolic acid copolymer is used as a matrix, polyvinyl alcohol is used as a cross-linking agent, and coated drug-loaded microspheres are formed through cross-linking and grafting of the matrix and the cross-linking agent; and then chitosan is used as a protective agent, chitosan and the coated drug-loaded microspheres are crosslinked and grafted to form double-coated composite drug-loaded microspheres, the chitosan in the composite drug-loaded microspheres is used as a shell, the coated drug-loaded microspheres are used as a core, and the linarin targeted slow-release nano drug-loaded system is obtained. Through the double-target design, the targeting property to cornea and lacrimal gland is enhanced, the treatment efficiency of the medicine is improved, stable release and continuous release of linarin are realized, and the problem of unstable release of the medicine is solved; in addition, the targeted slow-release nano drug-loading system is combined with the anti-inflammatory activity and the mitochondrial protection function of linarin, so that the side effects on eyes are reduced, and the safety is improved.

The invention belongs to the technical field of tumor treatment, and particularly relates to a metal polyphenol network coated drug-loaded mesoporous organic silicon nanoparticle and a preparation method and application thereof.The mesoporous organic silicon nanoparticle (MON) is prepared through a micelle / precursor co-template assembly method, then amination modification, carboxylation modification and drug co-loading are further conducted on the mesoporous organic silicon nanoparticle (MON), and the metal polyphenol network coated drug-loaded mesoporous organic silicon nanoparticle is obtained. The DQMCTH nano-particles are prepared through the steps that DQMCTH nano-particles are taken as a raw material, a copper salt solution and a tannic acid (TA) solution are added and mixed, then a coordination complexation reaction is conducted, hyaluronic acid (HA) is added for modification, and the DQMCTH nano-particles obtained through the method are in a sphere-like shape, regular in shape, uniform in distribution and free of obvious dendritic branches and central radial pore channels. The polypeptide is effectively protected by MPN and is subjected to HA targeted modification; more importantly, the DQMCTH nanoparticles prepared by the method disclosed by the invention show pH / GSH / HAase triple sensitive drug release, and cell and animal experiment results show that the DQMCTH nanoparticles prepared by the method disclosed by the invention have relatively high anti-tumor activity on a drug-resistant breast cancer model.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a composition containing a Nicodil multi-tablet structure and capable of realizing stepped slow controlled-release drug delivery. The invention relates to a composition containing a Nicodil multi-tablet structure stepped slow controlled-release drug delivery. The composition comprises a capsule shell and at least two micro-structure drug-containing bodies with different release rates, wherein the capsule shell is filled with the micro-structure drug-containing bodies; the microstructure drug-containing body is selected from at least two of a sustained-release tablet, an enteric-coated tablet and a quick-release tablet; and the microstructure drug-containing body contains an active drug Nicodil. The composition disclosed by the invention realizes rapid and stable slow-release drug release, overcomes side effects caused by a plasma ultra-safe interval due to burst release, ensures that a plasma treatment concentration is rapidly reached, realizes slow release, remarkably reduces degradation of active components in the composition, and improves the stability of the composition.

The invention discloses a nasal cavity coated drug-loaded stent and a preparation method thereof, and relates to the technical field of nasal cavity stents.The coated drug-loaded stent comprises a coated drug-loaded stent body and a drug coating covering the surface of the coated stent body, and the drug coating comprises a therapeutic drug and a carrier thereof; the carrier comprises a first polymer and a second polymer which have different drug loading functions; and a tissue regeneration guide layer can also be arranged on the medicine coating. The coated drug-loaded stent provided by the invention not only has a large wound surface contact area, but also can effectively regulate and control the drug release period, so that the drug release during the wound surface repair period is more stable, long-acting and controllable, thereby meeting the needs of nasal cavity wound surface repair.

Described herein are pharmaceutical compositions comprising extended-release pellets and optionally delayed release pellets, wherein each of the extended-release pellets and each of the delayed release pellets comprises a drug pellet and an outer coating; the outer coating of the extended-release pellets is an extended-release outer coating; the outer coating of the delayed release pellets is a delayed release outer coating; the outer coating of the extended-release pellets is an extended-release outer coating; the outer coating of the delayed release pellets is a delayed release outer coating; the drug pellet comprises about 15 wt.% to about 25 wt.% ibudilast, about 60 wt.% to about 70 wt.% sugar sphere, about 5 wt.% to about 10 wt.% hydroxypropyl methylcellulose, and about 4 wt.% to about 8 wt.% silicon dioxide; the extended-release outer coating comprises about 20 wt.% to about 55 wt.% ethyl cellulose, about 20 wt.% to about 55 wt.% hydroxypropyl methylcellulose, about 1 wt.% to about 4 wt.% triethyl citrate, and about 20 wt.% to about 25 wt.% talc, wherein the weight percentages of ethyl cellulose, hydroxypropyl methylcellulose, triethyl citrate, and talc are based on total weight of the extended-release outer coating; and the delayed release outer coating comprises about 55 wt.% to about 65 wt.% copolymer of methacrylic acid and ethyl acrylate, about 3 wt.% to about 9 wt.% triethyl citrate, and about 25 wt.% to about 35 wt.% talc, wherein the weight percentages of the copolymer of methacrylic acid and ethyl acrylate, triethyl citrate, and talc are based on total weight of the delayed release outer coating.

A method of preparing a pharmaceutical composition is provided. The method includes the deposition of a metal oxide layer(s) followed byapplying a polymer layer(s). This produces a pharmaceutical composition comprising a drug containing core enclosed by one or more metal oxide materials and one more polymer materials.

The present invention discloses a coating for a drug-eluting stent, which comprises a phase A and a phase B; the raw materials of the phase A include: carboxymethyl chitosan, ginkgo flavonoids, resveratrol, vascular endothelial growth factor, rapamycin, PEG-30 dimeric hydroxystearate, glycerol, silicone oil, and an aqueous acetic acid solution with a mass fraction of 0.1-0.5%; the raw materials of the phase B include: polylactic acid, polyethylene glycol, and dichloromethane. The coating for a drug-eluting stent proposed by the present invention not only has a good coating effect on drugs, but also can realize the continuous and slow release of the coated drugs from the surface of the stent, which not only restricts the proliferation of local vascular intimal cells, but also reduces the proliferation-promoting factors such as inflammatory reactions, thereby further enhancing the restriction effect on restenosis and improving the clinical practicability.

A pharmaceutical composition containing a metal oxide coated particle comprising 1) an amorphous solid dispersion (ASD) core containing an active pharmaceutical ingredient (API) and a polymer; and 2) a metal oxide coating, and the method of making said metal oxide coated particle by atomic layer deposition (ALD). The metal oxide coated particle is useful because it prevents the ASD from crystallization and helps maintain the ASD in an amorphous form.

The invention discloses a preparation method of inositol nicotinate tablets, and belongs to the technical field of pharmaceutical preparations. By optimizing the existing process and coating components, stable dissolution of drugs is realized, and the method comprises the following steps: dispersing inositol nicotinate in mixed oil to prepare an oil phase, mixing and emulsifying the oil phase and a water phase, performing spray drying to obtain drug milk powder, coating the drug milk powder with modified chitosan, and directly tabletting the coated drug milk powder and auxiliary materials. The preparation method comprises the following steps: uniformly dispersing inositol nicotinate in mixed oil to promote the inositol nicotinate to maintain the uniformity of the drug content in the subsequent process, and adsorbing solid particles on the surfaces of drug-containing oil drops through an emulsification technology to protect the drug components; coating components are reasonably designed, so that fixed-point release of the medicine is realized, the medicine is endowed with anti-pressure ability, and the medicine can be directly tableted; and the coated medicine particles are mixed with auxiliary materials and then are directly tableted, so that the process is simplified, and the coating structure of the medicine particles is protected at the same time. The preparation method can prepare the inositol nicotinate tablet with stable drug dissolution, and the inositol nicotinate tablet is good in taste and small in stimulation to gastric mucosa.

To provide tablets or capsules comprising coated particles comprising an active pharmaceutical ingredient (API)-containing core enclosed by one or more metal oxide layers and one or more polymer layers, and methods of preparing the same.SOLUTION: A tablet or capsule comprises individual particles comprising an active pharmaceutical ingredient (API)-containing core enclosed by an inner metal oxide layer and a polymer layer adjacent to the metal oxide layer, where the core has a median particle size between 0.1 μm and 20 μm on a volume average basis, and where the inner metal oxide layer has an average thickness of 0.1 nm to 30 nm and the polymer layer has an average thickness of 0.1 nm to 400 nm.SELECTED DRAWING: Figure 1

The present application relates to a drug delivery device and system, the drug delivery device having opposed proximal and distal ends, the drug delivery device comprising: a first tube providing a guidewire lumen; the second pipe fitting is arranged on the periphery of the first pipe fitting in a sleeving mode, the far end of the second pipe fitting is fixed to the far end of the first pipe fitting, the far end of the second pipe fitting comprises a medicine carrying section, the periphery of the medicine carrying section is used for being coated with medicine, the medicine carrying section is of a deformation structure capable of expanding outwards in the radial direction, and the near end of the second pipe fitting is in sliding fit with the first pipe fitting to adapt to deformation of the medicine carrying section; the deformation part is located in a radial gap between the first pipe fitting and the medicine carrying section, the deformation part is made of a deformation material, and the deformation part has an initial state attached to the first pipe fitting; in the working state, the drug loading section is radially expanded relative to the initial state to be expanded. After the medicine carrying section is conveyed to the expected position, the deformation piece can be switched to the working state, the medicine carrying section is attached to the pipe wall of the expected position after expanding, the coated medicine is slowly released to the pipe wall of the blood vessel, and the in-situ vascular stent is formed.

The invention belongs to the field of polymer chemistry and biomedical engineering, and discloses a construction method and application of a biomimetic membrane coated drug-loaded nano system. According to the system disclosed by the invention, small-molecule traditional Chinese medicine (sinomenine) is loaded in mesopores, and homologous cell membranes wrap drug-loaded nanoparticles to obtain a final nano-drug system which can effectively and passively target nasopharyngeal carcinoma cells. The sinomenine can cooperate with photothermal therapy to jointly induce mitochondrial injury, promote cell apoptosis and cause ICD immunoreaction, the sinomenine inhibits PD-L1 expression to relieve immunosuppression of T cells, meanwhile, infiltration of cytotoxic T cells in tumor sites is increased, distant metastasis of nasopharyngeal carcinoma can be inhibited by inhibiting MMPs and PD-L1, and the nasopharyngeal carcinoma can be inhibited by inhibiting MMPs and PD-L1. Therefore, the effects of enhancing nasopharynx cancer immunotherapy and inhibiting metastasis are achieved.

The present disclosure is directed to coated drug ion exchange particles and granules containing a resinous core, one or more active pharmaceutical agents and a coating comprising a cellulose acetate polymer optionally in combination with an enteric polymer. Related compositions and methods of making are disclosed.

The present application relates to the technical field of medicine, in particular to a coating composition, a coated pharmaceutical preparation prepared by the coating composition and a preparation method thereof.The coating composition comprises an inner coating composition and an outer coating composition; the inner coating composition is composed of low-viscosity hypromellose, sodium metabisulfite and the like, and the outer coating composition is composed of high-viscosity hypromellose, nano-zinc oxide, nano-titanium dioxide and the like.The coating composition of the present application realizes comprehensive protection of moisture, light and oxygen through the difference in viscosity and the redox potential gradient of spatial distribution, and the synergistic effect of the inner and outer layers significantly improves the stability of the pharmaceutical preparation.The coated pharmaceutical preparation prepared by the present application has excellent storage stability and is suitable for the development and application of light-sensitive drugs.

This invention relates to a pharmaceutical formulation, a coated pharmaceutical formulation, a method of preparation, and its application. The pharmaceutical formulation comprises a compound of formula I or a solvate thereof or a pharmaceutically acceptable salt thereof or a solvate thereof, a filler, a disintegrant, and a lubricant; based on the total mass of the pharmaceutical formulation, the mass percentage of the compound of formula I is 1%-50%, the mass percentage of the filler is 60%-90%, the mass percentage of the disintegrant is 1%-10%, and the mass percentage of the lubricant is 1%-10%. This formulation is used to prepare a medicament for the treatment and / or prevention of diseases related to GLP-1R. This invention achieves a better form of administration by mixing the active ingredient with excipients and undergoing formulation processing, resulting in a formulation with excellent in vivo absorption.

The application belongs to the technical field of medicines, and particularly relates to a targeted sustained-release nanometer drug delivery system of geniposide and a preparation method and application thereof. A polylactic acid-polyglycolic acid copolymer is used as a matrix, polyvinyl alcohol is used as a crosslinking agent, and the matrix and the crosslinking agent are crosslinked to form coated drug-loaded microspheres; then chitosan is used as a protective agent, and the chitosan and the coated drug-loaded microspheres are crosslinked to form double-wrapped composite drug-loaded microspheres, wherein the chitosan in the composite drug-loaded microspheres is a shell, and the coated drug-loaded microspheres are a core, so that the targeted sustained-release nanometer drug delivery system of geniposide is obtained. The application enhances the targeting of the cornea and the lacrimal gland through double-target design, improves the treatment efficiency of the drug, realizes stable release and sustained release of the geniposide, and overcomes the problem of unstable drug release; and the targeted sustained-release nanometer drug delivery system reduces the side effects on the eyes by combining the anti-inflammatory activity and the mitochondrial protection function of the geniposide, and improves the safety.

The invention relates to the technical field of medicines, in particular to a coating composition, a coating medicine preparation prepared from the coating composition and a preparation method of the coating medicine preparation. The coating composition comprises an inner-layer coating composition and an outer-layer coating composition, the inner-layer coating composition is prepared from low-viscosity hydroxypropyl methylcellulose, sodium pyrosulfite and the like, and the outer-layer coating composition is prepared from high-viscosity hydroxypropyl methylcellulose, nano zinc oxide, nano titanium dioxide and the like. According to the coating composition disclosed by the invention, comprehensive protection of moisture, light and oxygen is realized through differential viscosity, spatial distribution oxidation-reduction potential gradient and a synergistic effect of an inner layer and an outer layer, and the stability of a pharmaceutical preparation is remarkably improved. The coated medicine preparation prepared by the invention has excellent storage stability and is suitable for development and application of light-sensitive medicines.

Disclosed herein are new injection molding-coating devices for the continuous manufacturing of coated pharmaceutical tablets comprising one or more active pharmaceutical ingredients and one or more excipients. Also disclosed herein are methods for the continuous manufacture of coated pharmaceutical tablets using these new devices for the purpose application in the pharmaceutical and drug manufacturing industries.

The present invention discloses a preparation method of a membrane-coated drug sustained-release stent. First, a gentamicin-sodium alginate-polyvinyl alcohol mixed solution is prepared. By using impregnation oscillation, gel modification and cross-linking, and freeze-drying techniques, a degradable drug-coated membrane for drug sustained release is constructed on the surface of a porous stent. After that, an effective drug sustained-release effect is achieved, and it has a bactericidal and antibacterial effect for a certain period of time. It has good practicability, non-toxicity, and biodegradability, and can be used for preventing infection after bone repair surgery.

A pharmaceutical composition containing a metal oxide coated particle comprising 1) an amorphous solid dispersion (ASD) core containing an active pharmaceutical ingredient (API) and a polymer; and 2) a metal oxide coating, and the method of making said metal oxide coated particle by atomic layer deposition (ALD). The metal oxide coated particle is useful because it prevents the ASD from crystallization and helps maintain the ASD in an amorphous form.

The present disclosure relates to coated drug ion-exchange particles and granules comprising a resin core, one or more active pharmaceutical agents, and a coating comprising a cellulose acetate polymer, optionally in combination with an enteric polymer. Related compositions and methods of manufacture are disclosed.

Described herein are pharmaceutical compositions comprising extended-release pellets and optionally delayed release pellets, wherein each of the extended-release pellets and each of the delayed release pellets comprises a drug pellet and an outer coating; the outer coating of the extended-release pellets is an extended-release outer coating; the outer coating of the delayed release pellets is a delayed release outer coating; the outer coating of the extended-release pellets is an extended-release outer coating; the outer coating of the delayed release pellets is a delayed release outer coating; the drug pellet comprises about 15 wt. % to about 25 wt. % ibudilast, about 60 wt. % to about 70 wt. % sugar sphere, about 5 wt. % to about 10 wt. % hydroxypropyl methylcellulose, and about 4 wt. % to about 8 wt. % silicon dioxide; the extended-release outer coating comprises about 20 wt. % to about 55 wt. % ethyl cellulose, about 20 wt. % to about 55 wt. % hydroxypropyl methylcellulose, about 1 wt. % to about 4 wt. % triethyl citrate, and about 20 wt. % to about 25 wt. % talc, wherein the weight percentages of ethyl cellulose, hydroxypropyl methylcellulose, triethyl citrate, and talc are based on total weight of the extended-release outer coating; and the delayed release outer coating comprises about 55 wt. % to about 65 wt. % copolymer of methacrylic acid and ethyl acrylate, about 3 wt. % to about 9 wt. % triethyl citrate, and about 25 wt. % to about 35 wt. % talc, wherein the weight percentages of the copolymer of methacrylic acid and ethyl acrylate, triethyl citrate, and talc are based on total weight of the delayed release outer coating.

The present invention relates to a pharmaceutical formulation, a coated pharmaceutical formulation, a method for preparing same, and use thereof. The pharmaceutical formulation comprises a compound of formula I, or a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of the pharmaceutically acceptable salt thereof, a filler, a disintegrant, and a lubricant. On the basis of the total mass of the pharmaceutical formulation, the mass percentage of the compound of formula I is 1% to 50%, the mass percentage of the filler is 60% to 90%, the mass percentage of the disintegrant is 1% to 10%, and the mass percentage of the lubricant is 1% to 10%. The formulation is used for preparing a medicament for treating and / or preventing GLP-1R-related diseases. The present invention achieves a better administration form by mixing the active ingredient with excipients and formulating, and provides the formulation with excellent in vivo absorption.

The present disclosure provides compositions and methods of preparing compositions comprising using lipid containing pharmaceutical compositions that are prepared using an additive manufacturing technique such as a sintering or melting process. The pharmaceutical compositions may form self emulsifying drug delivery systems. The pharmaceutical compositions may form lipid coated drug particles that are formed from the melting of the lipid through the additive manufacturing process.

This invention relates to an anti-brittle enteric-coated gelatin hollow capsule shell, belonging to the field of hollow capsule production technology. Addressing the problems of low mechanical strength, easy breakage during storage and transportation, and increased brittleness due to high coating ratios in existing enteric-coated capsule shells, this invention significantly improves the anti-brittleness of the capsule shell while ensuring enteric properties. It utilizes a synergistic compounding of gelatin, humectants, surfactants, plasticizers, modifiers, disintegrants, opacifiers, and enteric coating materials, combined with a "step-by-step coating and online precise temperature-controlled drying" process. The product meets the pharmacopoeia's brittleness requirements for a 20g weight and passes a 100g weight strengthening test. It exhibits structural stability, low breakage rate, and is suitable for high-load packaging transportation and long-term storage, making it widely applicable to various enteric-coated drug formulations.

The present invention discloses a cell membrane-coated drug-loaded vesicle, a preparation method and an application, which mainly relate to the field of anti-tumor technology. It includes co-incubating a macrophage membrane solution with a TLR4 agonist RS09, and then extruding it back and forth 10 to 20 times using a 200nm polycarbonate membrane to obtain a cell membrane-coated nanovesicle loaded with a TLR4 agonist. The beneficial effect of the present invention is that it is used to target the delivery of TLR4 agonists to osteosarcoma tumor tissues, induce TAMs polarization, reshape the immunosuppressive TME, and efficiently kill osteosarcoma. This study achieved the dual purpose of regulating TME and killing tumors, providing a new strategy for the treatment of osteosarcoma.

The application provides a diatom-based nasal drug delivery sustained-release carrier and a preparation method and application thereof, and belongs to the technical field of biological processing forming and micro-nano drug carrier manufacturing. The preparation method comprises the following steps: diatomite particle cleaning and purification, loading of anti-rhinitis drugs on the purified diatomite particles, coating of polydopamine on the surfaces of the drug-loaded diatomite particles, and grafting of carboxymethyl chitosan on the surfaces of the polydopamine-coated drug-loaded diatomite particles. The method provided by the application can realize controllable and batch preparation of the diatom-based nasal drug delivery sustained-release carrier, and can realize controllable release of drugs in a stimulus-responsive manner under simulated pathological conditions of the nasal cavity. The preparation method provided by the application is simple and convenient, and the conditions are mild, so that batch preparation of the diatom-based nasal drug delivery sustained-release carrier can be realized. The prepared nasal drug delivery sustained-release carrier has excellent bioadhesion and drug sustained and controlled release performance, and is suitable for intelligent drug delivery and other related fields.

The invention relates to the technical field of medical apparatus and instruments, and provides a film-covered drug-loaded stent and a preparation method of the film-covered drug-loaded stent. The inner membrane is strip-shaped, and the outer side of the inner membrane is spirally attached to the inner wall of the stent body; the medicine carrying film is in a strip shape, is arranged on the outer side of the stent body corresponding to the inner film, and is attached to the outer side of the stent body and the inner film; the outer membrane is arranged on the outermost side of the stent, covers the stent body and the medicine carrying membrane and is attached to the part, not attached to the medicine carrying membrane, of the inner membrane, the outer membrane comprises a first area and a second area, the first area comprises the part corresponding to the inner membrane, and the second area comprises the part corresponding to the spiral gap of the inner membrane; the total endothelialization cycle of the second area, the stent body part corresponding to the second area and the inner side of the inner membrane is smaller than the degradation cycle of the first area and smaller than the degradation cycle of the inner membrane. The drug-loaded membrane is wrapped in the inner membrane and the outer membrane, and the outer membrane is divided into different areas, so that rapid endothelialization of the stent is realized, and excessive cell proliferation is avoided.